Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET
Company Participants
Matt Blazei - CORE IR
Claude Maraoui - Co-Founder President and Chief Executive Officer
Ernie De Paolantonio - Chief Financial Officer
Ramsey Alloush - General Counsel
Srinivas Sidgiddi - Vice President of Clinical Development and Medical Affairs
Conference Call Participants
Scott Henry - ROTH Capital Partners
Brandon Folkes - Cantor Fitzgerald
Operator
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical's Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call for approximately 30 days.
I would now like to turn the conference call over to Matt Blazei of CORE IR the company's Investor Relations firm. Please go ahead.
Matt Blazei
Good afternoon and thank you for participating in today's conference call. Joining me from Journey Medical Corporation's leadership team are Claude Maraoui, Co-Founder President and Chief Executive Officer; Ernie De Paolantonio, Chief Financial Officer; Ramsey Alloush, General Counsel; and Dr. Srinivas Sidgiddi, VP of Clinical Development and Medical Affairs who will be joining us for the Q&A session.
During this call management will be making forward-looking statements including statements that address Journey Medical’s expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q. The Form 8-K filed with the SEC today and the company's press release that accompanies this call, particularly the cautionary statements in it.
Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time sensitive information that is accurate only as of today, November 10, 2022. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call.